Turnstone biologics to present preclinical data for selected tumor-infiltrating lymphocyte (til) therapy at society for immunotherapy of cancer's (sitc) 38th annual meeting

San diego, sept. 28, 2023 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (til) therapy, today announced four posters reporting preclinical data for turnstone's selected til therapies will be presented at the 38 th annual meeting of the society for immunotherapy of cancer (sitc).
TSBX Ratings Summary
TSBX Quant Ranking